• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.

作者信息

Urosevic-Maiwald M, Mangana J, Dummer R

机构信息

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

出版信息

Ann Oncol. 2017 Jul 1;28(7):1673-1675. doi: 10.1093/annonc/mdx187.

DOI:10.1093/annonc/mdx187
PMID:28459947
Abstract
摘要

相似文献

1
Systemic inflammatory reaction syndrome during combined kinase inhibitor therapy following anti-PD-1 therapy for melanoma.黑色素瘤抗PD-1治疗后联合激酶抑制剂治疗期间的全身炎症反应综合征
Ann Oncol. 2017 Jul 1;28(7):1673-1675. doi: 10.1093/annonc/mdx187.
2
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.联合维莫非尼和考比替尼治疗 BRAF 突变型黑色素瘤。
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.
3
Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors.联合BRAF/MEK抑制剂治疗下的脱髓鞘性多发性神经根神经病
Eur J Cancer. 2017 Jun;78:103-104. doi: 10.1016/j.ejca.2017.03.018. Epub 2017 Apr 19.
4
Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.coBRIM 研究中考比替尼联合维莫非尼相关毒性的发生率、病程和处理。
Ann Oncol. 2017 May 1;28(5):1137-1144. doi: 10.1093/annonc/mdx040.
5
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.皮肤不良事件的比较概况：黑色素瘤中BRAF/MEK抑制剂联合疗法与BRAF单药疗法的对比
J Am Acad Dermatol. 2014 Dec;71(6):1102-1109.e1. doi: 10.1016/j.jaad.2014.09.002. Epub 2014 Oct 16.
6
Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.转移性黑色素瘤患者中使用靶向MAPK通路药物治疗相关不良事件的管理
Oncologist. 2017 Jul;22(7):823-833. doi: 10.1634/theoncologist.2016-0456. Epub 2017 May 18.
7
Possible macrophage activation in melanoma patients receiving combined kinase inhibitor therapy following anti-PD-1 therapy: a cytokine profiling study of two cases.抗PD-1治疗后接受联合激酶抑制剂治疗的黑色素瘤患者中可能的巨噬细胞激活：两例细胞因子分析研究
Ann Oncol. 2017 Oct 1;28(10):2624-2625. doi: 10.1093/annonc/mdx325.
8
Rapid evolution of combination therapy in melanoma.黑色素瘤联合治疗的快速发展
N Engl J Med. 2014 Nov 13;371(20):1929-30. doi: 10.1056/NEJMe1411158.
9
Skin cancer: BRAF and MEK inhibitors-good news comes in twos!皮肤癌：BRAF和MEK抑制剂——好消息成双而至！
Nat Rev Clin Oncol. 2014 Dec;11(12):683. doi: 10.1038/nrclinonc.2014.183. Epub 2014 Oct 21.
10
Gene Expression Profiling in -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib.BRAF 突变型黑色素瘤的基因表达谱分析显示，vemurafenib 治疗预后不良的患者亚群可通过 cobimetinib 联合 vemurafenib 克服。
Clin Cancer Res. 2017 Sep 1;23(17):5238-5245. doi: 10.1158/1078-0432.CCR-17-0172. Epub 2017 May 23.

引用本文的文献

1
Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies.免疫药物-药物相互作用影响免疫检查点抑制剂治疗的疗效和安全性。
Chem Res Toxicol. 2024 Jul 15;37(7):1086-1103. doi: 10.1021/acs.chemrestox.4c00067. Epub 2024 Jun 24.
2
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.免疫检查点抑制剂的致命性系统性炎症综合征：病例报告和文献系统评价。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-005841.
3
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.
新辅助纳武利尤单抗治疗后发生迟发性细胞因子释放综合征：病例报告及文献复习。
Immunotherapy. 2021 Sep;13(13):1071-1078. doi: 10.2217/imt-2020-0329. Epub 2021 Jul 21.
4
Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib.达拉非尼联合曲美替尼治疗患者的急性肾损伤的临床特征。
Nephrol Dial Transplant. 2022 Feb 25;37(3):507-514. doi: 10.1093/ndt/gfaa372.
5
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.B-RAF/MEK 抑制剂序贯治疗联合免疫检查点抑制剂或反之在 B-RAF 阳性转移性黑色素瘤中的皮肤不良反应：单机构病例系列研究。
J Immunother Cancer. 2019 Jan 8;7(1):4. doi: 10.1186/s40425-018-0475-y.
6
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.先前接受过基于程序性细胞死亡蛋白 1 治疗的黑色素瘤患者中 BRAF 加 MEK 抑制的耐受性和疗效。
Cancer. 2019 Mar 15;125(6):884-891. doi: 10.1002/cncr.31889. Epub 2018 Dec 6.